RU2012125827A - Применение аналога тестостерона и агониста 5-нт1а для лечения сексуальной дисфункции - Google Patents
Применение аналога тестостерона и агониста 5-нт1а для лечения сексуальной дисфункции Download PDFInfo
- Publication number
- RU2012125827A RU2012125827A RU2012125827/15A RU2012125827A RU2012125827A RU 2012125827 A RU2012125827 A RU 2012125827A RU 2012125827/15 A RU2012125827/15 A RU 2012125827/15A RU 2012125827 A RU2012125827 A RU 2012125827A RU 2012125827 A RU2012125827 A RU 2012125827A
- Authority
- RU
- Russia
- Prior art keywords
- ht1a
- testosterone
- analogue
- testosterone analogue
- sexual dysfunction
- Prior art date
Links
- 201000001880 Sexual dysfunction Diseases 0.000 title claims abstract 8
- 231100000872 sexual dysfunction Toxicity 0.000 title claims abstract 8
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical class O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 150000003515 testosterones Chemical class 0.000 claims abstract 20
- 239000003723 serotonin 1A agonist Substances 0.000 claims abstract 11
- 239000000203 mixture Substances 0.000 claims abstract 10
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 10
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 claims abstract 9
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 claims abstract 9
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 claims abstract 8
- 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 claims abstract 8
- 230000001568 sexual effect Effects 0.000 claims abstract 8
- 239000003814 drug Substances 0.000 claims abstract 4
- 238000004519 manufacturing process Methods 0.000 claims abstract 4
- 206010057671 Female sexual dysfunction Diseases 0.000 claims abstract 2
- 206010057672 Male sexual dysfunction Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Abstract
1. Применение аналога тестостерона и агониста 5-HT1A для изготовления лекарственного средства для лечения сексуальной дисфункции, где указанный 5-HT1A высвобождается по существу за один час и указанный аналог тестостерона - за 3,5-5,5 часов до сексуальной активности.2. Применение аналога тестостерона, ингибитора ФДЭ5 и агониста 5-HT1A для изготовления лекарственного средства для лечения сексуальной дисфункции, где указанный 5-HT1A высвобождается по существу за один час, указанный ингибитор ФДЭ5 за 1-2 ч и указанный аналог тестостерона - за 3,5-5,5 ч до сексуальной активности.3. Применение по п.1 или 2, где указанная сексуальная дисфункция представляет собой женскую сексуальную дисфункцию.4. Фармацевтическая композиция, включающая аналог тестостерона и агонист 5-HT1A, где указанная композиция предназначена для высвобождения по существу указанного 5-HT1A за один час и указанного аналога тестостерона - за 3,5-5,5 ч до сексуальной активности.5. Фармацевтическая композиция, включающая аналог тестостерона, ингибитор ФДЭ5 и агонист 5-HT1A, где указанная композиция предназначена для высвобождения по существу указанного 5-HT1A за один час, указанного ингибитора ФДЭ5 - за 1-2 ч и указанного аналога тестостерона - за 3,5-5,5 ч до сексуальной активности.6. Набор, включающий, по меньшей мере, одну фармацевтическую композицию, включающую аналог тестостерона и, по меньшей мере, одну композицию, включающую агонист 5-НТ1А, где указанный набор дополнительно включает инструкции по введению указанных композиций.7. Набор, включающий, по меньшей мере, одну фармацевтическую композицию, которая включает аналог тестостерона, по меньшей мере, одну фармацевтическую композици�
Claims (8)
1. Применение аналога тестостерона и агониста 5-HT1A для изготовления лекарственного средства для лечения сексуальной дисфункции, где указанный 5-HT1A высвобождается по существу за один час и указанный аналог тестостерона - за 3,5-5,5 часов до сексуальной активности.
2. Применение аналога тестостерона, ингибитора ФДЭ5 и агониста 5-HT1A для изготовления лекарственного средства для лечения сексуальной дисфункции, где указанный 5-HT1A высвобождается по существу за один час, указанный ингибитор ФДЭ5 за 1-2 ч и указанный аналог тестостерона - за 3,5-5,5 ч до сексуальной активности.
3. Применение по п.1 или 2, где указанная сексуальная дисфункция представляет собой женскую сексуальную дисфункцию.
4. Фармацевтическая композиция, включающая аналог тестостерона и агонист 5-HT1A, где указанная композиция предназначена для высвобождения по существу указанного 5-HT1A за один час и указанного аналога тестостерона - за 3,5-5,5 ч до сексуальной активности.
5. Фармацевтическая композиция, включающая аналог тестостерона, ингибитор ФДЭ5 и агонист 5-HT1A, где указанная композиция предназначена для высвобождения по существу указанного 5-HT1A за один час, указанного ингибитора ФДЭ5 - за 1-2 ч и указанного аналога тестостерона - за 3,5-5,5 ч до сексуальной активности.
6. Набор, включающий, по меньшей мере, одну фармацевтическую композицию, включающую аналог тестостерона и, по меньшей мере, одну композицию, включающую агонист 5-НТ1А, где указанный набор дополнительно включает инструкции по введению указанных композиций.
7. Набор, включающий, по меньшей мере, одну фармацевтическую композицию, которая включает аналог тестостерона, по меньшей мере, одну фармацевтическую композицию, которая включает ингибитор ФДЭ5, и, по меньшей мере, одну композицию, которая включает агонист 5-НТ1А, где указанный набор дополнительно включает инструкции по введению указанных композиций.
8. Применение по п.1 или 2, где указанная сексуальная дисфункция представляет собой мужскую сексуальную дисфункцию.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06076976A EP1925307A1 (en) | 2006-11-03 | 2006-11-03 | Use of 3-alpha-androstanediol in the treatment of sexual dysfunction |
| EP06076976.7 | 2006-11-03 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009120990/15A Division RU2463054C2 (ru) | 2006-11-03 | 2007-11-02 | Применение тестостерона и агониста 5-нт1a для лечения сексуальной дисфункции |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2012125827A true RU2012125827A (ru) | 2013-12-27 |
| RU2646447C2 RU2646447C2 (ru) | 2018-03-05 |
Family
ID=37846101
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009120988/15A RU2464027C2 (ru) | 2006-11-03 | 2007-11-02 | Применение 3-альфа-андростендиола, необязательно в сочетании с ингибитором фосфодиэстеразы 5, при лечении половой дисфункции |
| RU2009120992/15A RU2491073C2 (ru) | 2006-11-03 | 2007-11-02 | Применение 3-андростандиола, необязательно в сочетании с агонистом 5-ht1а для лечения сексуальной дисфункции |
| RU2009120990/15A RU2463054C2 (ru) | 2006-11-03 | 2007-11-02 | Применение тестостерона и агониста 5-нт1a для лечения сексуальной дисфункции |
| RU2012125827A RU2646447C2 (ru) | 2006-11-03 | 2012-06-20 | ПРИМЕНЕНИЕ АНАЛОГА ТЕСТОСТЕРОНА И АГОНИСТА 5-НТ1а ДЛЯ ЛЕЧЕНИЯ СЕКСУАЛЬНОЙ ДИСФУНКЦИИ |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009120988/15A RU2464027C2 (ru) | 2006-11-03 | 2007-11-02 | Применение 3-альфа-андростендиола, необязательно в сочетании с ингибитором фосфодиэстеразы 5, при лечении половой дисфункции |
| RU2009120992/15A RU2491073C2 (ru) | 2006-11-03 | 2007-11-02 | Применение 3-андростандиола, необязательно в сочетании с агонистом 5-ht1а для лечения сексуальной дисфункции |
| RU2009120990/15A RU2463054C2 (ru) | 2006-11-03 | 2007-11-02 | Применение тестостерона и агониста 5-нт1a для лечения сексуальной дисфункции |
Country Status (27)
| Country | Link |
|---|---|
| US (10) | US8653051B2 (ru) |
| EP (5) | EP1925307A1 (ru) |
| JP (8) | JP2010509212A (ru) |
| KR (6) | KR20090111803A (ru) |
| CN (6) | CN101563086B (ru) |
| AU (3) | AU2007314734B2 (ru) |
| BR (3) | BRPI0717856A2 (ru) |
| CA (3) | CA2668320C (ru) |
| CY (1) | CY1117191T1 (ru) |
| DK (1) | DK2086544T3 (ru) |
| ES (1) | ES2561946T3 (ru) |
| HR (1) | HRP20160108T1 (ru) |
| HU (1) | HUE026752T2 (ru) |
| IL (5) | IL198459A (ru) |
| ME (1) | ME02410B (ru) |
| MX (3) | MX2009004696A (ru) |
| NO (3) | NO20092145L (ru) |
| NZ (3) | NZ577393A (ru) |
| PH (2) | PH12014501440A1 (ru) |
| PL (1) | PL2086544T3 (ru) |
| PT (1) | PT2086544E (ru) |
| RS (1) | RS54541B1 (ru) |
| RU (4) | RU2464027C2 (ru) |
| SI (1) | SI2086544T1 (ru) |
| UA (4) | UA101948C2 (ru) |
| WO (3) | WO2008054214A2 (ru) |
| ZA (3) | ZA200903835B (ru) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101292492B1 (ko) | 2004-05-11 | 2013-08-01 | 이모셔널 브레인 비.브이. | 약제학적 제형물 및 여성 성기능 부전의 치료에서 그것의용도 |
| EP1790343A1 (en) | 2005-11-11 | 2007-05-30 | Emotional Brain B.V. | Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction |
| EP1925307A1 (en) * | 2006-11-03 | 2008-05-28 | Emotional Brain B.V. | Use of 3-alpha-androstanediol in the treatment of sexual dysfunction |
| EP2266568A1 (en) | 2009-05-26 | 2010-12-29 | Æterna Zentaris GmbH | Use of LHRH antagonists in combination with PDE V inhibitors for the treatment of sex hormone dependent disorders |
| EP2266567A1 (en) | 2009-05-26 | 2010-12-29 | Æterna Zentaris GmbH | Use of cetrorelix in combination with PDE V inhibitors for the treatment of sex hormone dependent disorders |
| CA2835845C (en) * | 2011-05-13 | 2020-07-28 | Emotional Brain B.V. | Drug delivery system |
| CA2856520C (en) | 2011-11-23 | 2021-04-06 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| JP5828923B2 (ja) | 2014-01-30 | 2015-12-09 | 国立大学法人高知大学 | ニッケル粉の製造方法 |
| CN106029270B (zh) | 2014-02-21 | 2017-09-08 | 国立大学法人高知大学 | 镍粉的制造方法 |
| JP6406613B2 (ja) | 2014-04-15 | 2018-10-17 | 住友金属鉱山株式会社 | 含有する炭素及び硫黄の濃度を低減するニッケル粉の製造方法 |
| CN103947533B (zh) * | 2014-05-15 | 2015-12-16 | 青岛理工大学 | 生长环境可控的磁化水工厂化豆芽菜生产系统 |
| RU2600845C2 (ru) | 2014-07-04 | 2016-10-27 | Общество С Ограниченной Ответственностью "Консорциум-Пик" | Применение производных оксатриазолий-5-олата для лечения сексуальных расстройств |
| US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3251436A (en) * | 1965-03-16 | 1966-05-17 | Dayton Steel Foundry Co | Spot-type disk brake |
| US3976776A (en) | 1972-12-06 | 1976-08-24 | Mead Johnson & Company | Tranquilizer process employing N-(heteroarcyclic)piperazinylalkylazaspiroalkanediones |
| US4521421A (en) * | 1983-09-26 | 1985-06-04 | Eli Lilly And Company | Treatment of sexual dysfunction |
| ZA848005B (en) | 1983-10-17 | 1985-05-29 | Duphar Int Res | Blood-pressure lowering piperazine derivatives |
| US4596795A (en) | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
| US4640921A (en) | 1986-02-04 | 1987-02-03 | Bristol-Myers | Treatment of sexual dysfunction with buspirone |
| US5015646A (en) | 1987-08-28 | 1991-05-14 | Bristol-Myers Squibb Co. | Pharmaceutically useful polymorphic modification of buspirone |
| US4877774A (en) | 1987-09-09 | 1989-10-31 | The United States Of America As Represented By The Department Of Health And Human Services | Administration of steroid hormones |
| CA1335106C (en) | 1989-02-27 | 1995-04-04 | John Mehnert Schaus | Ring-substituted 2-amino-1,2,3,4-tetra-hydronaphthalenes |
| US5447912A (en) | 1989-09-18 | 1995-09-05 | Senetek, Plc | Erection-inducing methods and compositions |
| US5250534A (en) | 1990-06-20 | 1993-10-05 | Pfizer Inc. | Pyrazolopyrimidinone antianginal agents |
| US5431922A (en) * | 1991-03-05 | 1995-07-11 | Bristol-Myers Squibb Company | Method for administration of buspirone |
| GB9301192D0 (en) | 1993-06-09 | 1993-06-09 | Trott Francis W | Flower shaped mechanised table |
| US5565466A (en) | 1993-08-13 | 1996-10-15 | Zonagen, Inc. | Methods for modulating the human sexual response |
| RU2152787C2 (ru) | 1994-06-02 | 2000-07-20 | Дан Рига | Лекарство против стресса, против снижения уровня активности и против старения и способ его получения |
| ES2139077T3 (es) | 1994-06-02 | 2000-02-01 | Dan Riga | Medicamento contra el estres, la degeneracion y el envejecimiento y proceso para su fabricacion. |
| WO1996026940A1 (en) | 1995-03-01 | 1996-09-06 | Kyowa Hakko Kogyo Co., Ltd. | Imidazoquinazoline derivatives |
| CA2215307A1 (en) | 1995-03-14 | 1996-09-19 | Vivus, Incorporated | Pharmaceutical compositions and kits for preventing erectile dysfunction |
| US5731339A (en) | 1995-04-28 | 1998-03-24 | Zonagen, Inc. | Methods and formulations for modulating the human sexual response |
| WO1996036339A2 (en) * | 1995-05-15 | 1996-11-21 | Beth Israel Hospital | Use of dihydrotestosterone compounds for treating male sexual dysfunction |
| GB9514464D0 (en) | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Medicaments |
| US6251436B1 (en) | 1995-09-29 | 2001-06-26 | L.A.M. Pharmaceutical Corporation | Drug preparations for treating sexual dysfunction |
| US6242198B1 (en) | 1996-07-25 | 2001-06-05 | Cambridge Neuroscience, Inc. | Methods of treatment of eye trauma and disorders |
| WO1998058633A2 (en) | 1997-06-23 | 1998-12-30 | Queen's University At Kingston | Microdose therapy of vascular conditions by no donors |
| US20040014761A1 (en) | 1997-10-28 | 2004-01-22 | Place Virgil A. | Treatment of female sexual dysfunction with phosphodiesterase inhibitors |
| US5877216A (en) | 1997-10-28 | 1999-03-02 | Vivus, Incorporated | Treatment of female sexual dysfunction |
| US20020013304A1 (en) * | 1997-10-28 | 2002-01-31 | Wilson Leland F. | As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness |
| AU740758B2 (en) | 1997-10-28 | 2001-11-15 | Vivus, Inc. | Treatment of female sexual dysfunction |
| US6246436B1 (en) * | 1997-11-03 | 2001-06-12 | Agilent Technologies, Inc | Adjustable gain active pixel sensor |
| TW542719B (en) | 1998-02-23 | 2003-07-21 | Pfizer Res & Dev | Method of treating impotence due to spinal cord injury |
| US6403605B1 (en) | 1998-05-29 | 2002-06-11 | Queen's University At Kingston | Methods for the normalization of sexual response and amelioration of long term genital tissue degradation |
| UA67802C2 (ru) | 1998-10-23 | 2004-07-15 | Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. | ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ ДЛЯ ПЕРОРАЛЬНОГО ПРИМЕНЕНИЯ С КОНТРОЛИРУЕМЫМ ВЫСВОБОЖДЕНИЕМ ИНГИБИТОРА цГМФ ФДЭ-5 (ВАРИАНТЫ), СПОСОБ ЕЕ ПОЛУЧЕНИЯ И СПОСОБ ЛЕЧЕНИЯ ЭРЕКТИЛЬНОЙ ДИСФУНКЦИИ |
| CA2365782A1 (en) | 1999-04-30 | 2000-11-09 | William E. Pullman | Treatment of female arousal disorder |
| US7258850B2 (en) | 1999-05-04 | 2007-08-21 | Aradigm Corporation | Methods and compositions for treating erectile dysfunction |
| US6632419B2 (en) | 1999-05-04 | 2003-10-14 | Aradigm Corporation | Increasing libido in humans via acute testosterone administration |
| US6428769B1 (en) | 1999-05-04 | 2002-08-06 | Aradigm Corporation | Acute testosterone administration |
| WO2000078328A2 (de) | 1999-06-17 | 2000-12-28 | Armin Johannes Becker | VERWENDUNG VON WACHSTUMSHORMON (hGH) ZUR THERAPIE SEXUELLER FUNKTIONSSTÖRUNGEN |
| RU2180591C2 (ru) * | 1999-12-24 | 2002-03-20 | Государственное научное предприятие Московский научно-исследовательский институт психиатрии МЗ РФ | Средство для лечения сексуальных дисфункций у мужчин |
| DE10016548A1 (de) | 2000-04-03 | 2001-10-11 | Bayer Ag | Polyurethan-Dispersionen |
| US6313172B1 (en) | 2000-04-13 | 2001-11-06 | Allergan Sales, Inc. | Methods and compositions for modulating alpha adrenergic receptor activity |
| US6242436B1 (en) * | 2000-06-15 | 2001-06-05 | William Charles Llewellyn | Use of 5alpha-androstanediol or 5alpha-androstanedione to increase dihydrotestosterone levels in humans |
| US7198801B2 (en) | 2000-08-03 | 2007-04-03 | Antares Pharma Ipl Ag | Formulations for transdermal or transmucosal application |
| US20030139384A1 (en) | 2000-08-30 | 2003-07-24 | Dudley Robert E. | Method for treating erectile dysfunction and increasing libido in men |
| US20040092494A9 (en) | 2000-08-30 | 2004-05-13 | Dudley Robert E. | Method of increasing testosterone and related steroid concentrations in women |
| ATE460939T1 (de) | 2000-08-30 | 2010-04-15 | Unimed Pharmaceuticals Llc | Verfahren zur behandlung von erektionsstörungen und steigerung der libido bei männern |
| WO2002026214A1 (en) | 2000-09-29 | 2002-04-04 | Solvay Pharmaceuticals B.V. | Ion-strength independent sustained release pharmaceutical formulation |
| US20060287335A1 (en) | 2000-11-28 | 2006-12-21 | Wyeth | Serotonergic agents for treating sexual dysfunction |
| HUP0400528A2 (hu) * | 2000-12-15 | 2004-06-28 | Pfizer Inc. | Neuropeptidáz Y inhibitor alkalmazása férfiak szexuális funkciózavarának kezelésére alkalmas gyógyszerkészítmény előállítására |
| US20020107230A1 (en) | 2000-12-22 | 2002-08-08 | Waldon R. Forrest | Methods and formulations for the treatment of female sexual dysfunction |
| MXPA03007960A (es) | 2001-03-06 | 2003-12-04 | Cellegy Pharma Inc | Compuestos y metodos para el tratamiento de desordenes urogenitales. |
| HRP20030751A2 (en) | 2001-03-28 | 2005-08-31 | Pfizer Inc. | N-phenpropylcyclopentyl-substituted glutaramide derivatives as nep inhibitors for fsad |
| EP1260225A1 (en) * | 2001-05-18 | 2002-11-27 | Pantarhei Bioscience B.V. | A pharmaceutical composition for use in hormone replacement therapy |
| US20030027804A1 (en) | 2001-06-27 | 2003-02-06 | Van Der Hoop Roland Gerritsen | Therapeutic combinations for the treatment of hormone deficiencies |
| US20030022875A1 (en) * | 2001-07-27 | 2003-01-30 | Wilson Leland F. | As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness |
| UA78974C2 (en) | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
| US20040259852A1 (en) | 2003-06-18 | 2004-12-23 | White Hillary D. | Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome |
| US20050065158A1 (en) * | 2003-07-16 | 2005-03-24 | Pfizer Inc. | Treatment of sexual dysfunction |
| WO2005007166A1 (en) * | 2003-07-16 | 2005-01-27 | Pfizer Limited | Treatment of sexual dysfunction |
| DE60303854T2 (de) | 2003-11-11 | 2006-08-10 | Mattern, Udo | Nasenformulierung mit kontrollierter Freisetzung von Sexualhormonen |
| WO2005094827A1 (en) * | 2004-03-30 | 2005-10-13 | Kestrel Pharmaceuticals Inc. | Methods for treating sexual dysfunction |
| BRPI0510074A (pt) | 2004-04-22 | 2007-10-16 | Boehringer Ingelheim Int | composições farmacêuticas para o tratamento de distúrbios sexuais ii |
| KR101292492B1 (ko) * | 2004-05-11 | 2013-08-01 | 이모셔널 브레인 비.브이. | 약제학적 제형물 및 여성 성기능 부전의 치료에서 그것의용도 |
| US20070154533A1 (en) | 2005-04-13 | 2007-07-05 | Dudley Robert E | Method of increasing testosterone and related steriod concentrations in women |
| WO2006127057A1 (en) | 2005-05-24 | 2006-11-30 | Lyle Corporate Drvelopment, Inc. | Non-systematic vaginal administration of estrogen and an androgen for the treatment of sexual dysfunction |
| WO2006125642A1 (en) | 2005-05-27 | 2006-11-30 | Antares Pharma Ipl Ag | Methods and apparatus for transdermal or transmucosal application of testosterone |
| WO2007054791A2 (en) | 2005-11-08 | 2007-05-18 | L'oréal | Androgen glucuronides as markers of androgenic activity |
| EP1790343A1 (en) | 2005-11-11 | 2007-05-30 | Emotional Brain B.V. | Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction |
| EP1925307A1 (en) * | 2006-11-03 | 2008-05-28 | Emotional Brain B.V. | Use of 3-alpha-androstanediol in the treatment of sexual dysfunction |
| RS54235B1 (sr) | 2007-11-28 | 2015-12-31 | Ucb Pharma Gmbh | Polimorfni oblik rotigotina |
-
2006
- 2006-11-03 EP EP06076976A patent/EP1925307A1/en not_active Ceased
-
2007
- 2007-02-11 ME MEP-2016-33A patent/ME02410B/me unknown
- 2007-02-11 UA UAA200905654A patent/UA101948C2/ru unknown
- 2007-02-11 UA UAA200905653A patent/UA103592C2/ru unknown
- 2007-02-11 UA UAA200905652A patent/UA100119C2/ru unknown
- 2007-11-02 CA CA2668320A patent/CA2668320C/en not_active Expired - Fee Related
- 2007-11-02 BR BRPI0717856-5A2A patent/BRPI0717856A2/pt active Search and Examination
- 2007-11-02 EP EP07834663.2A patent/EP2086544B1/en active Active
- 2007-11-02 ZA ZA200903835A patent/ZA200903835B/xx unknown
- 2007-11-02 KR KR1020097011486A patent/KR20090111803A/ko not_active Ceased
- 2007-11-02 WO PCT/NL2007/050534 patent/WO2008054214A2/en not_active Ceased
- 2007-11-02 BR BRPI0718396-8A2A patent/BRPI0718396A2/pt not_active IP Right Cessation
- 2007-11-02 KR KR20157004613A patent/KR20150038251A/ko not_active Ceased
- 2007-11-02 WO PCT/NL2007/050533 patent/WO2008054213A2/en not_active Ceased
- 2007-11-02 AU AU2007314734A patent/AU2007314734B2/en not_active Ceased
- 2007-11-02 JP JP2009535227A patent/JP2010509212A/ja active Pending
- 2007-11-02 HR HRP20160108T patent/HRP20160108T1/hr unknown
- 2007-11-02 AU AU2007314735A patent/AU2007314735B2/en not_active Ceased
- 2007-11-02 ZA ZA200903836A patent/ZA200903836B/xx unknown
- 2007-11-02 NZ NZ577393A patent/NZ577393A/xx not_active IP Right Cessation
- 2007-11-02 ZA ZA200903837A patent/ZA200903837B/xx unknown
- 2007-11-02 KR KR1020097011485A patent/KR20090115113A/ko not_active Ceased
- 2007-11-02 US US12/513,355 patent/US8653051B2/en active Active
- 2007-11-02 AU AU2007314736A patent/AU2007314736B2/en not_active Ceased
- 2007-11-02 JP JP2009535226A patent/JP2010509211A/ja not_active Withdrawn
- 2007-11-02 CN CN2007800474487A patent/CN101563086B/zh not_active Expired - Fee Related
- 2007-11-02 US US12/513,358 patent/US8575139B2/en not_active Expired - Fee Related
- 2007-11-02 MX MX2009004696A patent/MX2009004696A/es not_active Application Discontinuation
- 2007-11-02 DK DK07834663.2T patent/DK2086544T3/en active
- 2007-11-02 ES ES07834663.2T patent/ES2561946T3/es active Active
- 2007-11-02 RU RU2009120988/15A patent/RU2464027C2/ru not_active IP Right Cessation
- 2007-11-02 PT PT78346632T patent/PT2086544E/pt unknown
- 2007-11-02 RU RU2009120992/15A patent/RU2491073C2/ru not_active IP Right Cessation
- 2007-11-02 EP EP07834664A patent/EP2086545A2/en not_active Withdrawn
- 2007-11-02 KR KR1020097011483A patent/KR101578224B1/ko not_active Expired - Fee Related
- 2007-11-02 MX MX2009004693A patent/MX2009004693A/es active IP Right Grant
- 2007-11-02 CA CA2668317A patent/CA2668317C/en not_active Expired - Fee Related
- 2007-11-02 CN CN2013102891472A patent/CN103381270A/zh active Pending
- 2007-11-02 NZ NZ577392A patent/NZ577392A/xx not_active IP Right Cessation
- 2007-11-02 JP JP2009535228A patent/JP2010509213A/ja active Pending
- 2007-11-02 CN CN201410844093.6A patent/CN104524580A/zh active Pending
- 2007-11-02 EP EP07834665A patent/EP2086548A2/en not_active Withdrawn
- 2007-11-02 MX MX2009004695A patent/MX2009004695A/es not_active Application Discontinuation
- 2007-11-02 CN CNA2007800491317A patent/CN101573119A/zh active Pending
- 2007-11-02 UA UAA201214342A patent/UA115647C2/uk unknown
- 2007-11-02 CA CA2668316A patent/CA2668316C/en not_active Expired - Fee Related
- 2007-11-02 CN CN201310556256.6A patent/CN103599536A/zh active Pending
- 2007-11-02 EP EP15167346.4A patent/EP2937086A1/en not_active Withdrawn
- 2007-11-02 RU RU2009120990/15A patent/RU2463054C2/ru not_active IP Right Cessation
- 2007-11-02 WO PCT/NL2007/050535 patent/WO2008054215A2/en not_active Ceased
- 2007-11-02 KR KR1020167028902A patent/KR101796887B1/ko not_active Expired - Fee Related
- 2007-11-02 CN CNA2007800462422A patent/CN101557812A/zh active Pending
- 2007-11-02 PL PL07834663T patent/PL2086544T3/pl unknown
- 2007-11-02 US US12/513,357 patent/US8648060B2/en active Active
- 2007-11-02 SI SI200731745T patent/SI2086544T1/sl unknown
- 2007-11-02 NZ NZ577390A patent/NZ577390A/xx not_active IP Right Cessation
- 2007-11-02 KR KR1020157022168A patent/KR20150099620A/ko not_active Ceased
- 2007-11-02 RS RS20160069A patent/RS54541B1/sr unknown
- 2007-11-02 BR BRPI0717963-4A2A patent/BRPI0717963A2/pt not_active IP Right Cessation
- 2007-11-02 HU HUE07834663A patent/HUE026752T2/en unknown
-
2009
- 2009-04-30 IL IL198459A patent/IL198459A/en active IP Right Grant
- 2009-04-30 IL IL198461A patent/IL198461A/en active IP Right Grant
- 2009-04-30 IL IL198460A patent/IL198460A/en active IP Right Grant
- 2009-06-03 NO NO20092145A patent/NO20092145L/no not_active Application Discontinuation
- 2009-06-03 NO NO20092143A patent/NO343597B1/no not_active IP Right Cessation
- 2009-06-03 NO NO20092146A patent/NO20092146L/no not_active Application Discontinuation
-
2012
- 2012-06-20 RU RU2012125827A patent/RU2646447C2/ru not_active IP Right Cessation
- 2012-07-10 US US13/545,916 patent/US8669242B2/en active Active
-
2013
- 2013-09-06 JP JP2013185156A patent/JP5748238B2/ja not_active Expired - Fee Related
- 2013-10-08 US US14/049,005 patent/US9211334B2/en not_active Expired - Fee Related
- 2013-10-16 JP JP2013215284A patent/JP2014055142A/ja active Pending
-
2014
- 2014-01-03 US US14/147,393 patent/US20140121189A1/en not_active Abandoned
- 2014-01-03 US US14/147,415 patent/US20140121190A1/en not_active Abandoned
- 2014-01-08 JP JP2014001289A patent/JP2014111608A/ja active Pending
- 2014-06-20 PH PH12014501440A patent/PH12014501440A1/en unknown
- 2014-08-12 PH PH12014501821A patent/PH12014501821A1/en unknown
-
2015
- 2015-03-16 IL IL237786A patent/IL237786A0/en unknown
- 2015-05-07 JP JP2015094573A patent/JP6357131B2/ja not_active Expired - Fee Related
- 2015-12-04 US US14/960,204 patent/US9597335B2/en not_active Expired - Fee Related
-
2016
- 2016-02-12 CY CY20161100116T patent/CY1117191T1/el unknown
- 2016-10-27 IL IL248563A patent/IL248563B/en active IP Right Grant
-
2017
- 2017-02-21 US US15/438,547 patent/US10314848B2/en not_active Expired - Fee Related
- 2017-05-10 JP JP2017093563A patent/JP2017132809A/ja active Pending
-
2019
- 2019-05-14 US US16/412,276 patent/US20190262359A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2012125827A (ru) | Применение аналога тестостерона и агониста 5-нт1а для лечения сексуальной дисфункции | |
| CY1114448T1 (el) | Φαρμακευτικες συνθεσεις και χρηση αυτων στην αγωγη της γυναικειας σεξουαλικης δυσλειτουργιας | |
| HN2004000490A (es) | Procedimiento para la preparacion de una composicion farmaceutica solida administrable oralmente | |
| AR077199A1 (es) | Composicion farmaceutica y procedimiento de tratamiento para la anticoncepcion de emergencia | |
| MX2013000001A (es) | Composición farmaceutica de liberacion prolongada y acción retardada que comprende dapoxetina para administaracion oral. | |
| BR0308663A (pt) | Uso de inibidores de il-18 para o tratamento e/ou prevenção de doenças vasculares periféricas | |
| AR077125A1 (es) | Combinaciones farmaceuticas utiles para tratar el vhc | |
| AR077138A1 (es) | Composiciones farmaceuticas utiles para tratar el vhc | |
| NO20076219L (no) | Farmasoytisk formulering med apomorfin for bukkal administrering | |
| UA93709C2 (ru) | 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций | |
| WO2008116890A3 (en) | Pharmaceutical compositions comprising flibanserin and a further agent in the treatment of sexual disorders | |
| TW200722081A (en) | New therapeutic combinations for the treatment or prevention of depression | |
| GT200600307A (es) | Formas de dosificacion de liberacion retardada oral altamente biodisponibles de succinato de o-desmetilvenlafaxina | |
| NZ593199A (en) | Milnacipran for the long-term treatment of fybromyalgia syndrome | |
| PA8586301A1 (es) | Formulaciones de liberacion prolongada en forma de suspension | |
| EA200800783A1 (ru) | Композиция тразодона для введения один раз в день | |
| BR0317095A (pt) | Uso de uma combinação contendo um inibidor da transcriptase reversa sem ser de nucleosìdeo (nnrti) com um inibidor citocromo p450, tal como inibidores da protease | |
| DE602004019528D1 (de) | Usammensetzungen zur behandlung rekurrenten aphthen in der mundhöhle | |
| MXPA05008403A (es) | Uso de acido comestible en formas de dosis solidas farmaceuticas de rapida dispersion. | |
| UA102111C2 (ru) | Фармацевтическая композиция в виде разовой пероральной дозы, которая содержит леводопу, карбидопу и энтакапон или их соли | |
| AR052322A1 (es) | Compuestos de n-benzoil-estaurosporina, procesos para su preparacion y composicion farmaceutica | |
| PL2020999T3 (pl) | Kompozycje zawierające alfa-ketoglutaran i ich zastosowanie do modulowania wydajności mięśniowej | |
| CL2008002223A1 (es) | Compuestos derivados de 9-desoxo-9a-metil-9a-aza-9a-homoeritromicina a 2'-o-sustituida; proceso de preparación; compuesto intermediario; composición farmacéutica; y su uso en el tratamiento y/o profilaxis de la malaria. | |
| PA8789101A1 (es) | Composición farmacéutica estable que comprende una sal de vinflunina hidrosoluble | |
| WO2007027476A3 (en) | Treating premature ejaculation using gabapentin and pregabalin prodrugs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HZ9A | Changing address for correspondence with an applicant | ||
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20201103 |